A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A method of treating sleep apnea is provided. The method including the step of administering 12.5 mg to 25.0 mg of ephedrine before going to bed to a patient in need of treating the sleep apnea. Preferably, 5.0 mg to 100.0 mg of the ephedrine is administered about one hour before going to bed, ephedra containing 5.0 mg to 100.0 mg of the ephedrine is administered, the ephedrine is administered 15 to 45 minutes before going to bed, and/or the ephedrine or ephedra containing the ephedrine is in a form of immediate release, extended release, or sustained release.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

A biochemical scaffold for regulating mammalian cell function. The biochemical scaffold includes a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and the vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation at defined frequency ranges for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by liquid medium, and, when the biochemical scaffold is delivered to and, thus, in communication with biological tissue, the biochemical scaffold induces specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof, the biochemical activities including increased bioavailability of ATP.

The present disclosure relates to a composition for preventing hair loss or promoting hair growth, which contains a mixture of cucumber, eggplant and snail extracts as an active ingredient. The composition according to the present disclosure, which contains a mixture of cucumber, eggplant and snail extracts as an active ingredient, has been confirmed to increase the expression of hepatocyte growth factor (HGF), keratinocyte growth factor (KGF) and insulin-like growth factor 1 (IGF-1) in dermal papilla cells which are known to play a critical role in the induction of new hair follicles and maintenance of hair growth, exhibit hair-growing effect comparable to that of minoxidil in a hair growth test for depilated 6-week-old C57BL/6 mice, and exhibit hair loss-improving effect in a clinical test for human. Accordingly, it can be usefully used as a cosmetic composition or a pharmaceutical composition for external application to skin for preventing hair loss or promoting hair growth.